Clinical Research Directory

Inclusion Criteria: * Participant is at least two (2) years of age, AND Participant is suspected of acute viral respiratory infection by a healthcare professional, AND * Participant is within five (5) days of symptom onset, AND Participant is experiencing two or more of the following symptoms: Fever of \>100.0°F/ 37.8°C or chills, Cough, Fatigue, New loss of taste or smell, Congestion or runny nose, Shortness of breath or difficulty breathing, Sore throat, Muscle or body aches, Headache -The Participant and/or legally authorized representative is willing to undergo the informed consent/Assent process prior to study participation. A minor will need the documented consent of their parent or legal guardian unless the site has an HREC waiver for parental consent for minors. Exclusion Criteria: * Participant is currently enrolled in a study to evaluate an investigational drug or experimental treatment * Participants with an active nosebleed * Participant has undergone a nasal wash or nasal aspirate procedure on day of enrolment * Participant has tested positive for COVID-19 within the last 45 days * Participant has received a nasal vaccine (i.e. FluMist®) within the past 30 days. * Participant has received antiviral medications for Influenza (Amantadine, Rimantadine, Ribavirin, Oseltamivir, Zanamivir) in the previous 45 days. * Participant has received medication or treatment for COVID-19 infection in the last 45 days (including antivirals (such as Paxlovid), convalescent plasma therapy, monoclonal antibody treatment (mAb), Remdesivir, long-acting antibody (LAAB) treatment (Evusheld) * Participant is unable to meet all inclusion criteria as listed above